Investing in Healthcare Without the Illusion: Red Flags, Real Value, and the Future of AI-Driven Due Diligence
Healthcare investing carries extraordinary potential. It influences how quickly new diagnostics reach patients, how efficiently we prevent disease, how much time clinical teams spend on real work rather than administrative burden, and how rapidly innovation becomes accessible. But despite its impact, the sector remains one of the most misunderstood, emotionally charged, and high-risk investment categories.
The tension is clear. Investors want returns with measurable impact. Founders need capital to move their projects through long regulatory pathways. Policymakers want safety. Patients want solutions. And in between these forces, a complex ecosystem emerges where hope, science, and incentives meet.
In this episode of The Bridge, together with Dr Peter M Kovacs, I spoke with investor and former hedge fund portfolio manager Ales Vavra, who brings a rare combination of technology, financial discipline, and a healthy level of skepticism. His experience managing short positions, especially in biotech and pharmaceutical companies, has given him a unique perspective.
Not the perspective of someone looking for miracles, but of someone who has learned how to identify danger before others see it.
The Illusion of Miracles
Every sector has hype cycles, but in healthcare, the emotional component is stronger. Diseases like Alzheimer, cancer, Parkinson, and chronic metabolic disorders create a natural desire for breakthroughs. This desire makes people vulnerable to unrealistic claims, especially when companies present themselves as being on the verge of delivering something revolutionary.
Ales explained that the biggest frauds he observed often appeared in the central nervous system space. Alzheimer in particular attracts enormous public interest because the need is global and personal. When a company positions itself as having discovered something simple, fast-acting, and transformative, investors jump quickly. And that is exactly where the illusion begins.
The first illusion is speed.
There is no fast track to solving the hardest biological challenges in the world. Drug development takes time. Clinical validation is slow because it must be slow. Anything that claims otherwise requires deeper investigation.
The second illusion is simplicity.
If a biotech project claims to solve a complex disease with a single mechanism and very limited data, it is almost always misleading.
The third illusion is certainty.
Science does not offer one hundred percent guarantees. Real evidence grows step by step. Fraud grows in a straight line.
These illusions create pressure for positivity. When someone expresses skepticism, they risk being seen as the person who does not want a cure to succeed. Ales described the experience of being the one in the room who questions everything. It is uncomfortable. But it is necessary.
Because people who invest in illusions lose money.
People who rely on illusions in healthcare lose more than that. They lose time that could have been directed toward real progress.
Why Skepticism is a Leadership Skill
Skepticism is not negativity. It is not cynicism.
It is discipline.
Skepticism protects investors from avoidable failure. It protects founders from building on unstable foundations. It protects patients from false hope. And it protects the entire ecosystem from wasting resources on projects that are not grounded in evidence.
Ales shared that one of the most powerful strategies he learned during his years of shorting biotech stocks was simple.
Understand the management team.
Look at their history. Look at the companies they worked for. Look at previous claims. Patterns repeat. If a team has a record of questionable behavior, it is a major red flag. If a company does not respond transparently to critical reports or if their communication strategy relies heavily on emotional appeal, the signals are even stronger.
Skepticism becomes a leadership skill when it is used to guide decision-making, not block innovation. We need investors who ask questions that push founders toward clarity. We need founders who welcome skepticism because it sharpens their work. And we need advisors who can translate complex science into understandable risk profiles.
Healthy skepticism expands the space for real innovation.
Blind optimism does the opposite.
Simplicity as a Strategy
One of the most memorable parts of our conversation was Ales saying that the best projects are usually simple. Not simple in science, but simple in explanation. When a founder cannot explain in basic terms what their product does, for whom, and why it works, it is a warning sign.
This is even more important in fields like diagnostics, AI-driven decision support, or digital health. These solutions touch real patients and real workflows. If the value proposition is unclear, adoption becomes slow or impossible.
Simplicity does not mean lack of sophistication. It means clarity. The kind of clarity that builds trust and accelerates collaboration.
Investors want to understand:
What problem does the technology solve?
How does it integrate with existing clinical practice?
What is the path to regulatory approval?
How long will validation take?
Where does the revenue model sit?
What is the risk of data bias?
How will the solution scale?
What data exists today that proves the idea is moving in the right direction?
The companies that answer these questions with transparency and structure are the ones that attract serious funding. They do not need hype. They need precision.
The Future of AI-Driven Due Diligence
AI is transforming the investment landscape.
But not in the way most people imagine.
AI is not about asking a chatbot whether a startup is worth investing in. That is neither safe nor responsible. Instead, AI becomes powerful when investors use it to process large datasets, analyze patterns, identify outliers, and compare claims with scientific evidence.
Ales described how much easier evaluation has become now that data-driven tools exist. In the past, he had to read countless pages of scientific documents manually. Today, he uploads datasets into secure AI environments that analyze trends without introducing noise.
But AI has limits.
AI is only as good as the data it receives.
AI can amplify bias if used carelessly.
AI cannot interpret regulatory nuance or ethical risk the way an experienced human can.
The most responsible approach is a hybrid.
Use AI to accelerate understanding.
Use experts to validate judgment.
Over the next decade, we will see AI becoming more embedded in every stage of healthcare development. Drug discovery, biomarker identification, predictive diagnostics, and personalized prevention will depend on sophisticated algorithms. And investors who learn to navigate AI today will be the ones best positioned to support the next era of healthcare.
Yet the most important principle does not change.
Technology must serve people, not replace them.
Diversification is Protection
Despite all the innovation happening in biotechnology, diagnostics, and digital health, investing is still a risk-based activity. Diversification remains one of the most effective ways to manage uncertainty.
Ales pointed out something surprising. Many investors still fail to diversify. They select one project and follow a hero or zero mindset. This approach is understandable emotionally but dangerous financially.
Diversification is not only about protecting returns.
It is a way to support a broader landscape of innovation.
When investors spread risk across multiple validated ideas, more solutions reach the market. More founders receive the opportunity to advance their work. More patients eventually benefit.
Diversification is responsible investing.
It is also strategic leadership.
Why Good Advisors Matter
The complexity of healthcare innovation makes expert guidance non-negotiable. Even the most experienced investors cannot master every domain. And that is not a weakness. It is reality.
Ales was transparent about the need to hire specialists. His team often pays experts significant fees for just a few hours of focused advice because those hours can prevent years of misdirection.
The challenge is that not all advisors are equal.
Some are superficial.
Some are biased.
Some lack practical experience.
The key is to find advisors who combine credibility with independence. People who understand both the scientific and business landscapes. People who are not afraid to say no. People who ground decisions in evidence, not enthusiasm.
A good advisor will ask difficult questions that reveal the quality of a project.
A weak advisor will reinforce your biases.
A strong advisor will protect your investment.
A weak advisor will increase your risk.
Choosing the right expertise is not a cost.
It is an investment in clarity.
Balancing Innovation and Human Behavior
One of the most refreshing parts of our discussion was when we shifted from investment strategy to human behavior. Ales touched on lifestyle choices, the hype around longevity, and the gap between what people know and what they actually do.
Simple habits like taking the stairs instead of the lift matter more than many of the trending longevity solutions. We do not need complex tools to improve our health. We need discipline. But discipline does not trend on social media.
This is where prevention becomes powerful. And where technology can help people make better choices instead of offering shortcuts.
True health progress depends on small, consistent behaviors.
Innovation should be designed to support these behaviors, not replace them.
Building the Future of Evidence-Based Healthcare
The healthcare sector is changing faster than ever. Disease prevention is becoming central. AI is moving from experimentation to real-world application. Clinical trials are becoming more digital, more global, and more integrated with real-world evidence. And investors are increasingly selective. They want validation. They want clear regulatory paths. They want technologies that solve real problems.
This shift is healthy. It pushes founders to be more disciplined. It encourages investors to support projects with impact. And it forces everyone to think globally. If a technology can scale across markets, cultures, and clinical environments, its potential becomes transformational.
Healthcare progress depends on collaboration. Investors, clinicians, engineers, regulators, data scientists, and patients must work together. No single group can accelerate innovation alone.
The Bridge was created to support exactly this.
Connecting science, clinical research, and AI-driven innovation to make healthcare accessible, effective, and humane. And conversations like this one exist to guide the ecosystem toward decisions that matter.
The greatest opportunity in healthcare investing comes from combining clear thinking, responsible skepticism, and a deep understanding of how innovation translates into real patient outcomes.
The illusions disappear when we focus on evidence.
The red flags become obvious when we understand human incentives.
The real value emerges when we integrate technology, prevention, and global collaboration.
The future of due diligence will be strengthened by AI, but steered by people who understand what is at stake.
Healthcare investing is not just about financial returns. It is about shaping a world where science serves humanity, where innovation reaches those who need it most. And where progress is grounded in truth, not hype. If you are building, investing in, or evaluating healthcare technologies and want to connect with a global network of experts, innovators, and decision makers, I invite you to reach out.
Together we can make prevention the standard, not the exception.
Timecode:
00:00 Introduction and Guest Background
01:44 Investment Strategies in Healthcare
03:13 Red Flags in Healthcare Investments
06:04 Role of AI in Investment Decisions
08:16 Advice for Healthcare Investors
12:01 Success Stories and Challenges
14:07 The Role of Sugar in Our Lives
14:55 Life Balance
15:43 The Hype and Reality of AI
18:40 Investment Challenges for Startups
21:48 Bitcoin and Long-Term Value
25:15 Personal Reflections and Future Outlook
26:17 Final Thoughts on Investment and Life02:31 Conclusion and Contact Information
Links:
Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/
Website: PavlinaWalter.com
Guests:
Ales Vavra https://www.linkedin.com/in/ales-vavra-6423475/
Peter M. Kovacs: https://www.linkedin.com/in/petermkovacs/
Episode Transcript:
Pavlina Walter: I would like to welcome here. Ales Vavra, we would like to today a little bit more, speak about the investments in healthcare sector. So I will ask you to actually introduce yourself to our audience and tell a little bit more about your experience in healthcare.
Dr. Peter M. Kovacs: Uh,
Ales Vavra: thank you for inviting me.
Dr. Peter M. Kovacs: Um, so where you started, so what was just very briefly, not from the kindergarten, just just your professional career.Yes, but,
Ales Vavra: uh, at the, at the first, I have to say that I'm not a. I was a programmer. Yeah, I'm, I'm, I'm, I'm text coding the programs and during this, my, let's say, short carry are, meet with a lot of new technologies and a lot of softwares and starting thinking like, uh, investor, that means what will happen as soon as I will buy the stock.Of companies, which tools I'm using every day in my, in my job. That's my beginning. And as a i, I did start as a, let's say, broker first take care of, uh, client's position and client's money. Then I was a portfolio manager of the hedge fund of Metatron Capital, which is, let's say. Daughter of J&T Bank. Private Czech Bank.Yeah, just Czech and Slovak Bank. Sorry. That's, that's my long story. Short. Yeah. And finally, finally, the fund, which I've managed was, uh, short only.
Ales Vavra: And it's mean. All my position was, uh, against the, the, the. The long position. I am hoping, uh, short means you are hoping that, uh, stock will go down in the future. Yes. That's first. That's my story. Yeah. Nothing important.
Dr. Peter M. Kovacs: And what was the key focus in your investment strategy? So do you have a, uh, an, any specific, um, industry or, or any specific, uh, yes.
Ales Vavra: Technology at the first, but, uh, uh, I. I, I have to say that I did see a lot of opportunities for shorts in, um, drugs, sectors mm-hmm.
And pharmacy, because there are the frauds and misleading investors. And, uh, I think that I make a lot of nice shorts against the, some, let's say miracles, which, um, unfortunately not happen.
Pavlina Walter: Can you actually. Like, say something more about it, because our audience is more from the healthcare sector, not the financial experts
Ales Vavra: as, as us.It's, uh, well, it's not easy to answer because I am watching as a, I don't want to say professional, but, um, the guy who did see a lot of, let's say, strange things first. A freelances is not exist. That's my first answer. If some, some projects, uh, has a, let's say, nice goes front of these projects very often is a hard, hard way to, to dig in or hard way to get it.And as soon as someone will tell you, I have a miracle for you. So quick. So easy. Yeah, just invest. Very probably not true.
Dr. Peter M. Kovacs: It's a red flag. It's the biggest red flag. Yes. Right? Yes, yes. 'cause there is no pill that cover solve all the diseases.
Ales Vavra: Yes. And especially if we are talking about, let's say, world's disease, world's biggest problem as a Alzheimer's.Mm-hmm. Problem, and so on and so on. It's this, this waste are so difficult.
Pavlina Walter: So you consider that the area of a CNS central nervous system like Alzheimer is the area where there is lots of throats, and then you have some other like examples for us.
Ales Vavra: Uh, it's a, it's, uh, some, some something. Uh, uh, I mean, yes, yes.For example, Cassava science is a, is was a fake, all, all, all FDA. Not all data, but on F1 and F two, there was a lot of mis misleading for investors and everyone wants to get a drug for Alzheimer's, but unfortunately, but as, as soon as you will have a see on the manage management and we'll, uh, we'll have a look, which companies did work for in the past, you can see, let's say some.Science, science. Science. Yes, there are some. There was, were two guy, two bad guys and working for similar company and was the misleading in foreign investor as well. And for in cassava there was, especially this guy was a unfortunately wrong guy. Hmm. So, but it's hard to, hard to answer because as soon as I will get this disease, I, I want to hope.Mm-hmm. But these things are not working like this. If you, something won't to. Unfortunately it could, could happen that will not happen.
Dr. Peter M. Kovacs: But it is the mistake that they didn't perform properly to due due diligence processes. I mean, the investors that they get so mislead, misled by this company. So how is it possible, because there are so long processes, right?
Ales Vavra: Yeah, I know, I know. Because it, it take takes, let's say years. Yes. I think seven or maybe eight. And the, the guys, which was were short as me. Did pay, let's say, a lot of, um, professors from university and opposite opinions to create, let's say, critical reports. But, uh, no one scared. No one scared these reports '
Dr. Peter M. Kovacs: cause everybody hoped that this should work.Yes. And
Ales Vavra: by the way, if you are against the, this. Something like this, you are, you are the bad guy because you don't want to be positive
Dr. Peter M. Kovacs: heal the
Ales Vavra: patients. You were against the the patients. It is not easy, but answer to your clients or to our audience is just be. Be a little skeptic. Not too much, but be a little skeptic.
Pavlina Walter: I have a question. Because you are not from the medical field, how come you can evaluate this kind of projects?
Ales Vavra: It's, it's, it's not easy because, but much easier for today because as soon as you will use a lot of AI tools. Mm-hmm. Yes. You can orient it very quickly. Yes. Because. In the past, I have to read a lot of text.
Mm-hmm. Texts. Mm-hmm. Uh, sorry. A lot of pages, a lot of books. And my focus is not the Be Biologists, but as soon as you will use AI tools, could. Help you and, uh, move to right direction, but mm-hmm. Be, be, be, be skeptic as well against ai. It's just
Dr. Peter M. Kovacs: a good hint. But, but not, no, no. Yes, it's not
Ales Vavra: 100%.Unfortunately. We are
Pavlina Walter: now discussing a lot with ai, the data protection, security, not disclosing confidential information. If you are using ai, you need to put some information that AI is able to give you some hints, for example. Yeah. Mm-hmm. So what kind of information you can disclose. Uh, and how you fit your AI to.I mean, to give you some kind of report or opinion, or even like, results already.
Ales Vavra: Okay. Uh, I, I, I will, I will tell you how, which tools I'm using mm-hmm. Every day and how I'm doing. Uh, first I think that much better to use AI tools for your own data. It mean find the, any robots or any application where, where could, could you put all your, your data and the, the algorithms will work only behind your data's much.
Uh, much better. Much better. For, for, for digging. We, we are saying digging because there are no not lot of, um, wrong noises and some, uh. How does it say it's, uh,
Dr. Peter M. Kovacs: this phantom data? Yes, yes.
Ales Vavra: That is, and I'm using, let's say for example, it's this tool calls. It's from Google. It's, uh, not, not a book. LM very, very useful.Mm-hmm. Very useful. You can put, uh, uh, interview like our mm-hmm. You can put your data. Mm-hmm. And as soon as you are good programmer, you can connect it to your own database. Mm-hmm. It is really good. That's, that's to which I'm using every day.
Pavlina Walter: Okay.
Ales Vavra: To, to be, let's say, oriented in, in large area of data.
Pavlina Walter: Mm-hmm. So coming back to your, like, previous focus on healthcare sector, so if we would be now investors, we would like to invest the money, what would be your advice to us? How you would guide us and what you would recommend?
Dr. Peter M. Kovacs: Where to start, where to start, what to evaluate, how to go.
Ales Vavra: It's, it's not easy, but first not to
Pavlina Walter: lose.
Ales Vavra: Of course. Of course. But as, as you said, anytime when someone invest, could happen, unfortunately. Anything, yes. Sure. First. Second, if you want to manage your risk, you can do it via, let's say. You, you not to put all your money on one project. Yes. Finally. Diversification. Yes. Diversification is really un but you will be so surprised how many investor did not do it.Yeah. Right. Because just believe only one thing want to be. Uh, say want to be hero or zero? Yeah, we are, we are calling this kamikaze as a style because it's, sometimes you are nice or no, sometime not, but unfortunately. But kamikaze a style is not definitely the way which your, you have to do, you have to do. And
Dr. Peter M. Kovacs: based on your experience and what you explained in the last few minutes, uh, so the personal behaviors is the main significant bias for the good investments.
Ales Vavra: Yeah. Yeah. Yeah. Yes, yes. But, uh, just use, use advisors. Yeah. It's, uh, let me give you some example. I, I'm, I'm, I don't know if I'm good in this business, but definitely I'm not a good cooker. I'm not good. Uh, bricklayer, I'm not a good, uh, anything. But if I need this type of job or work, I have to hire something.
Mm-hmm. Just hire advisor, maybe pay. Before put any investment for consulting, it's uh, it's the same like with a car. How many people visit the car room before they buy the car? But how many investors ask any other advisor which invest is good or not? Almost no one.
Pavlina Walter: We are talking about, uh, healthcare technologies.So they are very difficult, especially nowadays when the development goes so fast, how actually those kind of advisors can oriented, can be oriented. In this sector? Yeah. If you have some new application with ai, how they distinguish this application is much better than the other one. Mm-hmm. So they would tell me, Pavlina, invest money to this kind of application rather than to the one which you wanted.
Ales Vavra: As I said, it's not easy to answer basically, but. AI is really, uh, a good tool. Definitely. I'm pretty sure that as soon as we will make this interview after 10 years, AI will be there, but question will be, which project will be there, if you will have any project which is working on really big data, I guess.So it'll be good as we talk before, if you use your ring, your watches, your. Data from doctor collecting and create some, let's say, report or early warning. Nice one. Nice one. Mm-hmm. We are work on it. Yes. Nice one. Mm-hmm. For example, if to, it will be, goes together with your drinks, with your food. I mean not, um, your, um, I mean what, what you, what you are drinking or eating and, and finally if you will have a, let's say in toilet at some.It collection of data in toilets. It'll be, it's working already. Yeah, it's already working. I know, I know. It's sort of some existing project.
Pavlina Walter: What was your, the biggest success?
Ales Vavra: I mean, you mean on the short? Mm-hmm. Yes. Yes. The cassava science was my biggest mm-hmm. Biggest success because it was so clear that Yeah, the, the, the drug doesn't work, but.Timing is a good for this, my short, but as, as we said before, timing is a key point. Yeah. As you will find the, any future project, I mean, not you, your clients, timing is good as well because it, unfortunately, I have to say, that'll not happen immediately, but. You have to be patient. This the same case for the short cassava was nice.And mine Max. mine Max was a, another good one. It was a fake fake. Um, uh, if you cut a knife to the head, there is some special, um, how does it say? Some Gaza or something I think, and doesn't work as well, but yeah. But takes five years already. And there are a lot of, there are a lot of mid misleading investors in these sectors, for example, for losing weights.Mm-hmm. And be strong and so on, because not easy to, let's say, measure these successes. So.
Pavlina Walter: You touched a little bit this, okay. Weight loss, maybe longevity things. So what's your opinion about this sector right now?
Ales Vavra: I, I, I have to, um, I have to say again, I'm optimistic. I want to progress. I want to have a be in better life.But unfortunately, there are a lot of, let's say Misleadings, for example, longevity is a new, new age, but. How, how many people, how often anyone, let's say don't use Lyft. Yeah. As soon as every day you will not use a Lyft and will use the steps. It's a such a easy hack for longevity, but no one's doing it. No one's doing, but only because this is in the headlines and now, and now that's very sexy headline.
Yeah. It's very the, the same, the same. The, the sugar. Mm-hmm. The sugar. I, I'm happy that we are drinking water and I'm happy that my. My kids are drinking water as well. For me, it's hard to, let's say, understand how could, for example, companies like Coca-Cola use sugar for, for the future, for let's say after 20 years.Because su every, every, everybody knows that sugar is not a
Dr. Peter M. Kovacs: healthy eating.
Ales Vavra: Yes. But by the way, how, how many from this table are, let's say, eating ice cream? Ice cream is just a sugar and water. Water and water, yes. Nothing, yes cream, but yes, it's, it's original from the fruits. Mm-hmm. Some this is different.Let's say about alcohol. This is the same. Alcohol is, I, fortunately, I, I'm drinking alcohol. I'm not a drunker, but, but still drinking, but it's happening. Yes. Sometimes it's happening and, but I'm really know that it's not a best way how to long. Longer, but not a lot of stories starting when we meet each other and start drinking water.That's my answer. The life balance is a key point. Mm-hmm. For me,
Dr. Peter M. Kovacs: quite rare that we are going for water testing. Okay.
Ales Vavra: I'm sorry. I don't know if you understand, uh, answer your question. Yes. But, but mm-hmm. It's, uh, there are a lot of, let's say.
Dr. Peter M. Kovacs: New, new headlines. Yeah. But this hype is also biased. Many investors that it's a two, two big hype and also is a question we are living now.It's a booming, the ai, I see that it is also a big hype and how you can differentiate between the hype and the real values.
Ales Vavra: It's not easy answer, but uh, uh, AI is, uh, is, is here. And I think that will be there, let's say after 10 years, no doubt. But AI is not a. Put, put some text and create some, some, imagine some it's not AI or, or just the, let's say, asking what time is it or when the Second World War did start, it's not for ai, but it cost the money for the chips and chip sets for the developing languages, but for the electricity as well.I think that AI will be there, but uh, there will be. Much different levels. For example, some levels for the doctors, some levels for the university students, and some, some level for, let's say kids or parents for school is really good. Nice tool. But for what the cost and my answer is, uh, to, to stay for AI will be key point.If, let's say. Money will return back to the system because as soon as you will pay 20 US dollars for ChatGPT, it's uh, uh, losing money for the, the creating of ChatGPT. It's, uh, cost more than create, uh, revenue. And I think that AI will be there. Maybe we'll be much, much expensive and, and focusing for various specific.Issue maybe in the, in the, your segment for the developing drugs. I think that will spend, save a lot of time for developing, I guess so.
Dr. Peter M. Kovacs: I guess so. And that's money is also because time is money. Yes. It's money because
Ales Vavra: as soon as you, you have to pay some experts in the laboratories and, and you are wasting time and, and sources of, of course, yes.I will be and definitely will be there in the school sector. I think it's. Nice too for, for kids. Uh, when, when I was born was small, we are always reading book. Yeah. No one will read a book again. Mm-hmm. Everyone will be. Texting with a, with a, with a machine, with a chat. It's real.
Dr. Peter M. Kovacs: I saw a very nice study from MIT couple of weeks ago.They tested the, the people who are using check GPT, how their cognitive decline mm-hmm. Is visible because you are not thinking anymore.
Ales Vavra: Yes. But if you, you, you will, you will use, let's say pessimistic view of point. You can. Protect your brain to, to collapse. Yes. Yes. That, that was my answer. Sorry.
Dr. Peter M. Kovacs: Okay.Just turning back a bit to the investment part. So, uh, we are trying to have for, um, small startup companies, small biotech, MedTech companies, uh. Um, to go and to speed up, uh, the go to market strategy, it's very difficult because everybody's lacking financing. Uh mm-hmm. They, they, they're lacking, uh, uh, uh, experience and expertise.How do you see in the, in the optimal and the best case scenario? Uh, um, investment model, uh, 'cause there are a lot of investors. There are a lot of startups waiting for investment, but, um, the overlap is very small. So there are much more money on the market. There are a lot of startups, but they never meet each other.How is it possible how you could solve this, this dilemma?
Ales Vavra: I, I, I really don't know. Sorry. I really don't know, but, uh. Uh, maybe easy answer is just if the product is very simple. Every, everyone is understanding what product is for what, yeah, how does it work, and so on and so on. Maybe the answer is, uh. The simplicity.Yes. Yes. That may, maybe that's the reason because no one understand financing. No one, sorry. Yeah. Yeah. A few people only, and, but everyone's, everyone will be understand what, what, what is inside this class if it tastes good or not. That's my answer. But I'm not an expert, sorry.
Pavlina Walter: But I hope that at least you understand the financing.Yes. I, I guess so. I guess so. Guess so.
Ales Vavra: But I mean, uh, the other people, sorry. So
Pavlina Walter: yeah, I have a question. So if I would, um, like to invest to some portfolio, I can come to you and you will tell me like what would be the best, uh,
Ales Vavra: that's, that's my job. Yes. Yes. But as I said before. Just if you doesn't understand anything mm-hmm.Just hire advisor. Mm-hmm. Yes. Special advisor because we are many times doing in our company, because we don't, we don't have a chance to understand everything. I mean, we just pay special guy who understand something special. We are ready to pay really huge fee for let's say, two or three hours consulting, and then we know that we are doing maximum to get all the information.I think that could do
Dr. Peter M. Kovacs: everybody. Yeah, but I, I also had some quite bad experience with advisors. Even with the top five. Really? I'm so sorry. Sorry to hurry. It's also difficult to find them because, um, some of them, they're the big ones, uh, they are very superficial. Mm-hmm. Uh, the smaller ones, they are sometimes a bit biased because they don't have the enough experience.So it is also difficult to find the good advisor. Yes. I, I do,
Ales Vavra: I do agree. But life is difficult. Sorry. Yeah. And that's, yes. Investing is difficult. It's not, not, not, it's not easy. Mm-hmm. And it's. It's a fair say. It's much too complicated for me. I cannot invest. It's fair. Say Okay. Don't be afraid to say it.
Dr. Peter M. Kovacs: Okay. Because you are not confident. Yes. Because everyone,
Ales Vavra: every, everybody wants to have a nice sleep. Yeah. Without, without a ring or without, it's, it's normal.
Pavlina Walter: Okay. And then, um, also we touch a little bit the Bitcoin, even if we say we will not so speak about this topic. So what's your opinion about the bitcoin?
Ales Vavra: Ah, yeah, I'm sorry. Uh, it's hard to answer easy, but I'm not a big fan, unfortunately because, uh, it's, uh, just data database mm-hmm. Database. There is, uh, not a lot of other information in this database, and, and I, I, I believe. For hardworking. Mm-hmm. I believe the guy who did build, let's say some company which is there over 100 years, created a lot of position, created a lot of jobs, impacts, yes.Uh, big impacts for the community, for the state. Pay a lot of taxes. That's, that's, that's the way, which I believe the value as the value. Long-term value. As soon as you'll use the valuation of the Bitcoin only skill is that you will buy it before me for better price. The word can be built on this, let's say Ed.I think it's already there. Yes. I, I accept it already there, but definitely we will not, um, let's say change the, the fiat system or something like this. Is there, okay. I respect, but it's, I, I'm, I will be the last one on the planet, which you will buy the, the Bitcoin, I have to say. The last one will be me
Dr. Peter M. Kovacs: and you.You say that, so how you feel yourself? You, you are a pioneer or, or you are just some, some person with, with the extraordinary skills and mindset.
Ales Vavra: It's, uh, it's, uh, it's hard to answer, but, uh, I'm, I'm still, I'm, I'm not a how to answer, but let, let me answer it this way. I'm still thinking, still, still thinking about everything.And, uh, I'm, I'm, I'm, I'm not thinking about the only because when I'm doing sports or sleeping, maybe during the, the dreams, I, I, I started to write my dreams and you, you will not have, imagine what I'm dreaming about. It's crazy. But, but, but that's my answer. I'm, I'm still thinking and I still need the information, and that's my answer.Mm-hmm. If, if I'm good or not, I, I really don't know, but still. Work with the brain is a key point for, for longevity. I, I, I think so. I think so, definitely. Unless alcohol, of course.
Dr. Peter M. Kovacs: And you, you, you went many times against the mainstream and, uh, was it really hard or, or Yes, absolutely.
Ales Vavra: It's always hard. It's, it's always hard.It's always hard and, and, uh, it's a very, really big pressure from, because if, if I was a short and I was right, I will be only one guy in the room who will be happy because I will make money. Other guy in the room was upset. Yes. Yes. That, that's a key point. If I will tell you something wrong about your investment, you will not like me because
Dr. Peter M. Kovacs: you see something wrong with I don't.Yes,
Ales Vavra: but it's not easy. Not easy, not easy. But I'm happy to get a chance to be there and still thinking and uh, and I get a lot of new friends because from this area. Um, I get a lot of, let's say, new view of points. Really different thinking. Yeah. Yes. And, and definitely AI is, is, uh, really good, good tool for everyone, everyone in the room, really.
Dr. Peter M. Kovacs: And where do you see yourself in the next five, 10 years?
Ales Vavra: I hope still alive. I hope so. It's a good start. Yes, yes. And I hope that my, I hope that my family will be cool. Will be good. My wife and my to my sons. And then I really don't know. I, I, I think that I will still meet the very interesting people Yeah.During my life and still my brain will work. Yeah. But doesn't matter what I will do.
Dr. Peter M. Kovacs: And is it easy for you to shift quickly based on the circumstances,
Ales Vavra: uh, changes? Yes. It is not, not hard for me to, to switch. It depends on the project of the people and so on. It has to be so challenging for me and, uh, really nice.Let's say. Group of people or, or colleagues are very, it's, it, it was, I was so happy to work with very smart people in the past and very, let's say, dedicated positive. Yes, yes. It's, it's, it's, it was my, my, it was my, my for fortune, it was my. Best, best, best luck in the world after I've met my wife, of course.Okay.
Pavlina Walter: And if you would say the last positive comments for our audience or recommendation Yes. Is gonna be
Ales Vavra: yes. Don't afraid, don't afraid. Uh, if you want to invest, you have to accept some risk. But, uh, investment ha ha has a lot of ways, a lot of ways invest in. Your own health. It's invest, invest to the friends and friendship is investment.And if you want to invest money, just, just be, don't worry, but be, be careful. That's my answer.
Pavlina Walter: Excellent. Thank you.
Ales Vavra: Thank you so much,thank you for inviting. Thank you